Trial reportThe pharmacogenomics journal2012
Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.
Trial report in The pharmacogenomics journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020Pooled it
- From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Pharmacogenomics · 2018Pooled it
- Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.The Cochrane database of systematic reviews · 2017Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2014Pooled it
- Dopaminergic genetic variation moderates the effect of nicotine on cigarette reward.Psychopharmacology · 2016Trial
- Effects of nicotine deprivation and replacement on BOLD-fMRI response to smoking cues as a function of DRD4 VNTR genotype.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2014Trial
- Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Addiction (Abingdon, England) · 2013Trial
- The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013Trial
- The association of genetic polymorphisms within the dopaminergic system with nicotine dependence: A narrative review.Heliyon · 2024Review
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2023Review
- A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations.Frontiers in genetics · 2023Article
- A 5-Factor Framework for Assessing Tobacco Use Disorder.Tobacco use insights · 2021Article
- The VNTR 48 bp Polymorphism in theDiagnostics (Basel, Switzerland) · 2019Article
- Pathways to precision medicine in smoking cessation treatments.Neuroscience letters · 2018Review
- Pharmacogenetic Optimization of Smoking Cessation Treatment.Trends in pharmacological sciences · 2017Review
- Gender Considerations in Addiction: Implications for Treatment.Current treatment options in psychiatry · 2015Article
- Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome.Drug and alcohol dependence · 2014Article
- Pharmacogenetics of nicotine addiction: role of dopamine.Pharmacogenomics · 2014Review
- Implications of genome wide association studies for addiction: are our a priori assumptions all wrong?Pharmacology & therapeutics · 2013Review
- An Association between Emotional Responsiveness and Smoking Behavior.Journal of addiction · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Smokers (≥10 cigarettes per day, N=331) of European ancestry taking part in a double-blind placebo-controlled randomized trial of 12 weeks of treatment with bupropion along with counseling for smoking cessation were genotyped for a variable number of tandem repeats polymorphism in exon III of the dopamine D4 receptor gene. Generalized estimating equations predicting point-prevalence abstinence at end of treatment and 2, 6 and 12 months after the end of treatment indicated that bupropion (vs placebo) predicted increased odds of abstinence. The main effect of Genotype was not significant. A Genotype × Treatment interaction (P=0.005) showed that bupropion predicted increased odds of abstinence in long-allele carriers (odds ratios (OR)=1.31, P<0.0001), whereas bupropion was not associated with abstinence among short-allele homozygotes (OR=1.06, P=0.23). The Genotype × Treatment interaction remained when controlling for demographic and clinical covariates (P=0.01) and in analyses predicting continuous abstinence (P's≤0.054). Bupropion may be more efficacious for smokers who carry the long allele, which is relevant to personalized pharmacogenetic treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.